Page last updated: 2024-11-07

ketobemidone, n,n-dimethyl-3,3-diphenyl-1-methylallylamine drug combination

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ketobemidone, N,N-dimethyl-3,3-diphenyl-1-methylallylamine drug combination: contains ketobemidone & N,N-dimethyl-3,3-diphenyl-1-methylallylamine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID160082
MeSH IDM0056193

Synonyms (6)

Synonym
81605-86-9
1-propanone, 1-(4-(3-hydroxyphenyl)-1-methyl-4-piperidinyl)-, mixt. with n,n-dimethyl-4,4-diphenyl-3-buten-2-amine hydrochloride
ketobemidone, n,n-dimethyl-3,3-diphenyl-1-methylallylamine drug combination
1-[4-(3-hydroxyphenyl)-1-methylpiperidin-4-yl]propan-1-one--n,n-dimethyl-4,4-diphenylbut-3-en-2-amine--hydrogen chloride (1/1/1)
DTXSID101002082
n,n-dimethyl-4,4-diphenylbut-3-en-2-amine;1-[4-(3-hydroxyphenyl)-1-methylpiperidin-4-yl]propan-1-one;hydrochloride

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The mean plasma half-life of elimination (t1/2 beta) was about the same following oral (2."( Clinical pharmacokinetics and oral bioavailability of ketobemidone.
Anderson, P; Arnér, S; Bondesson, U; Boréus, LO; Hartvig, P, 1980
)
0.26

Bioavailability

ExcerptReferenceRelevance
"90 (SD) and the mean relative bioavailability of the mixture was slightly above 100%."( Analgesic effect and bioavailability of oral ketogan given as tablets or mixture to patients with chronic pain of malignant origin.
Kjaer, M; Nielsen, H, 1988
)
0.27
"The basic pharmacokinetics and oral bioavailability of ketobenmidone have been studied in 6 patients after surgery."( Clinical pharmacokinetics and oral bioavailability of ketobemidone.
Anderson, P; Arnér, S; Bondesson, U; Boréus, LO; Hartvig, P, 1980
)
0.26

Dosage Studied

ExcerptRelevanceReference
" The patients were six days in hospital and were dosed two days with tablets, two days with mixture and finally another two days with tablets."( Analgesic effect and bioavailability of oral ketogan given as tablets or mixture to patients with chronic pain of malignant origin.
Kjaer, M; Nielsen, H, 1988
)
0.27
" The low oral bioavailability and rapid elimination of ketobemidone demonstrated in this study suggest that the usual dosage recommendation for oral Ketogin (ketobemidone 5--10 mg every 6--7 h) in patients with severe pain is too low."( Clinical pharmacokinetics and oral bioavailability of ketobemidone.
Anderson, P; Arnér, S; Bondesson, U; Boréus, LO; Hartvig, P, 1980
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-199016 (72.73)18.7374
1990's3 (13.64)18.2507
2000's3 (13.64)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.78 (24.57)
Research Supply Index3.40 (2.92)
Research Growth Index4.18 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.78)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (20.83%)5.53%
Reviews1 (4.17%)6.00%
Case Studies1 (4.17%)4.05%
Observational0 (0.00%)0.25%
Other17 (70.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]